Novo Nordisk(US:NVO) Guan Cha Zhe Wang·2025-12-27 04:41Core Insights - Novo Nordisk's oral version of semaglutide (25mg) has received FDA approval for weight management, marking the world's first non-injection GLP-1 weight loss drug [1] - The semaglutide series is projected to generate nearly $29.3 billion in sales in 2024, closing the gap with Merck's Keytruda [1][3] - The approval of the oral formulation is expected to enhance patient convenience and adherence, further expanding market potential [1] Group 1: Product and Market Performance - In 2024, Novo Nordisk reported total revenue of 290.4 billion Danish Krone (approximately $42.15 billion), a 26% year-on-year increase, driven primarily by semaglutide sales [3] - The semaglutide product line generated sales of 201.8 billion Danish Krone (approximately $29.3 billion) in 2024, a nearly 40% increase from 2023 [3] - The diabetes and obesity care segment accounted for 93.6% of total revenue, with GLP-1 diabetes drugs holding a 55.1% market share globally [4] Group 2: Clinical and Regulatory Developments - The newly approved oral semaglutide (Wegovy) demonstrated significant weight loss in clinical trials, with participants losing an average of 16.6% of their body weight over 64 weeks [6] - Wegovy is expected to be commercially available in the U.S. by early 2026, with plans for submissions to other regulatory bodies in 2025 [6] - In China, Novo Nordisk's sales for GLP-1 drugs reached 10.52 billion Danish Krone (approximately $1.5 billion) in 2024, with a 19% year-on-year growth [7] Group 3: Competitive Landscape and Future Outlook - The core patent for semaglutide will expire in 2026, prompting over ten companies in China to submit applications for similar drugs, indicating a competitive race for biosimilars [10][11] - The global market for GLP-1 drugs is projected to reach $51.8 billion in 2024, with expectations to exceed $60 billion by 2025 and potentially reach $100 billion by 2030 [11] - Novo Nordisk and Eli Lilly dominate the GLP-1 market, holding approximately 86% of the market share, with significant growth potential for domestic alternatives as competition intensifies [12]